{{Rsnum
|rsid=4054823
|Chromosome=17
|position=13721707
|Orientation=plus
|GMAF=0.4421
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|summary=Associated with aggressive form of prostate cancer
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 20.5 | 47.3 | 32.1
| HCB | 30.7 | 53.3 | 16.1
| JPT | 22.3 | 50.0 | 27.7
| YRI | 4.1 | 40.1 | 55.8
| ASW | 17.5 | 42.1 | 40.4
| CHB | 30.7 | 53.3 | 16.1
| CHD | 25.0 | 50.9 | 24.1
| GIH | 20.8 | 53.5 | 25.7
| LWK | 23.1 | 45.4 | 31.5
| MEX | 17.5 | 59.6 | 22.8
| MKK | 25.3 | 42.2 | 32.5
| TSI | 17.6 | 59.8 | 22.5
| HapMapRevision=28
}}

[[rs4054823]] is a SNP in chromosomal region 17p12.

This SNP is associated with risk of aggressive [[prostate cancer]]. Most prostate cancers proceed slowly and can be successfully treated even if not detected early. A subset of prostate cancers are an aggressive form which is harder to treat, especially if not detected early. The aggressive form of prostate cancer accounts for an estimated 27,000 deaths annually in the US. 

A study of 4,829 and 12,205 patients with more and less aggressive disease, respectively, found that the frequency of [[rs4054823]](T;T) was consistently higher among patients with more aggressive compared with less aggressive disease in each of the seven populations studied (overall p = 2.1 x 10e-8). This is not a predictor of increased risk of prostate cancer. Instead, those who do get prostate cancer have a higher risk of it being the aggressive type if they have the risk factor. Those with the risk factor can benefit from more frequent prostate cancer exams, and more aggressive treatment if prostate cancer is found.{{PMID|20080650|OA=1
}}

In the news: [http://www.reuters.com/article/idUSTRE60A4W420100111 Gene may pinpoint most aggressive prostate cancer].

{{PMID Auto
|PMID=21308149
|Title=Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study
|OA=1
}}

{{PMID|21367958|OA=1
}} Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.

{{PMID|21520160}} Prostate cancer risk variants are not associated with disease progression.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}